Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma

Changhui Li,Bo Zhang,J. Guo,Fang Hu,Wei Nie,Xiaoxuan Zheng,Lixin Wang,Yuqing Lou,Yinchen Shen,Baohui Han,Xueyan Zhang

Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma

2019

Changhui Li
Bo Zhang
J. Guo
Fang Hu
Wei Nie
Xiaoxuan Zheng
Lixin Wang
Yuqing Lou
Yinchen Shen
Baohui Han
Xueyan Zhang

Background Whether epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy can delay the occurrence of brain metastasis (BM) is unclear.

Keywords:

Brain metastasis
Pharmacology
Mutant
Epidermal growth factor receptor
EGFR Tyrosine Kinase Inhibitors
Medicine
Tyrosine kinase
Lung
Chemotherapy
Adenocarcinoma
Internal medicine
Retrospective cohort study
Hazard ratio
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations